By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

OK

By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

Biogen

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial Pharmaceutical Technology19:25Spinraza Biotech Pharma

Biogen's Phase II/III SMA study for higher Spinraza dose meets goals Zacks16:05Spinraza Biotech Pharma

Eli Lilly's Alzheimer's drug faces UK agency block after Biogen's medicine rejection over cost, safety Benzinga13:55NICE Alzheimer's Health

Alzheimer's disease drug deemed too expensive for the NHS European Pharmaceutical Manufacturer13:10NICE Alzheimer's Health

Biogen's Alzheimer's drug secures UK approval, but an independent agency does not recommend reimbursement Benzinga18:49Alzheimer's NICE NHS

Leqembi authorised for early Alzheimer's in the UK European Pharmaceutical Manufacturer16:59Alzheimer's Pharma Biotech

Latest News

In the last 7 days

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial Pharmaceutical Technology19:25 6-Sept-24

Biogen to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference Biogen (Press Release)21:15 5-Sept-24

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals Zacks16:05 5-Sept-24

Biogen shares promising results for higher dose nusinersen in spinal muscular atrophy PMLiVE12:07 5-Sept-24

Biogen’s Higher-Dose Spinraza Shows Better Efficacy, But Franchise Stands To Lose Market Share Scrip Pharma Intelligence22:35 4-Sept-24

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says ENDPOINTS20:53 4-Sept-24

Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win FiercePharma16:52 4-Sept-24

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder Benzinga15:51 4-Sept-24

Clouds of Care Secures 5 Million Euros to Propel CNS Healthcare Innovation and appoints former… PR Newswire (Press Release)14:00 4-Sept-24

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit… GlobeNewswire (Press Release)12:35 4-Sept-24

Biogen Stock Declines 20.9% Year to Date: Time to Sell? Zacks14:34 3-Sept-24

Dyne Therapeutics Announces Key Leadership Appointments GlobeNewswire (Press Release)11:32 3-Sept-24

In the last month

Biopharma partnering monthly update: July 2024 Taylor Wessing10:53 29-Aug-24

Alzheimer’s Disease Drug Deemed Too Expensive for the NHS European Pharmaceutical Manufacturer13:10 28-Aug-24

Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact… GlobeNewswire (Press Release)15:17 26-Aug-24

Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety Benzinga13:55 26-Aug-24

Leqembi authorised for early Alzheimer's in the UK European Pharmaceutical Manufacturer16:59 23-Aug-24

Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli… GlobeNewswire (Press Release)12:27 23-Aug-24

England’s Cost Effectiveness Rejection Is Another Setback For Eisai And Biogen’s Leqembi Scrip Pharma Intelligence10:43 23-Aug-24

UK’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi Boston Globe21:10 22-Aug-24

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement Benzinga18:49 22-Aug-24

New Alzheimer's Drug Deemed Too Costly for UK's State-run Health Service News18.com17:00 22-Aug-24

Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive FiercePharma14:59 22-Aug-24

Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain JCN Newswire14:05 22-Aug-24

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE PMLiVE12:25 22-Aug-24

Biogen, Eisai’s Leqembi wins UK approval, but NHS coverage may be unlikely ENDPOINTS12:17 22-Aug-24

Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain Biogen (Press Release)10:27 22-Aug-24

Biogen sued for alleged PBM kickbacks scheme to boost Tecfidera in wake of generics FiercePharma16:38 21-Aug-24

Autoimmune Disorder Drug Delivery Devices Market Exceed Growth rate (CAGR) of 16.89% Through… Industry Today12:39 21-Aug-24

Biogen to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Biogen (Press Release)21:07 20-Aug-24

Lawsuit alleges Biogen schemed with PBMs to preserve Tecfidera market ENDPOINTS18:55 20-Aug-24

Is Wall Street Bullish or Bearish on Biogen Stock? Barchart16:00 20-Aug-24

Biogen Paid To Help Curb Generic Tecfidera Sales, Says Suit Law36003:51 20-Aug-24

Biogen gets US$1.5bn revolver International Financing Review08:36 16-Aug-24

Biogen Enhances Financial Flexibility with New Credit Facility TipRanks22:04 14-Aug-24

UAE approves Leqembi for treatment of Alzheimer's disease BioSpectrum Asia18:46 14-Aug-24

Metagenomi axes ALS program after seeing Biogen and Ionis flounder FierceBiotech15:05 14-Aug-24

"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab… JCN Newswire02:59 14-Aug-24

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates Biogen (Press Release)00:24 14-Aug-24

OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris… Business Wire (Press Release)10:31 13-Aug-24

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. The Motley Fool14:06 11-Aug-24

Chutes & Ladders—Biogen CMO Maha Radhakrishnan joins Sofinnova FierceBiotech13:44 9-Aug-24

view more headlines

6 Sept 19:25

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

Publication filters

Notifications

Unsubscribe from Breaking News

Sorry, no headlines or news topics were found. Please try different keywords.